Guardion® Receives approval from USPTO for expanded claims for its Proprietary Medical Device, the MAPCAT SF
October 23 2019 - 7:00AM
Guardion Health Sciences, Inc. (“Guardion” or the “Company”)
(Nasdaq: GHSI) announced that it has received approval from the
USPTO for additional claims reflected in a new patent for its
proprietary medical device, the MapcatSF®. The new patent will
issue October 29, 2019 as U.S. Patent No. 10,456,028 and is a
continuation patent on the original MapcatSF® patent, U.S. Patent
No. 9,486,136. This second patent on the MapcatSF® covers new
embodiments around the device that contain improvements related to
the accuracy of intensity measurements made with the device, as
well as patentably distinct features around photodiode detector
calibrations. Also, there will be a patent term adjustment for the
patent of 307 days.
Michael Favish, Guardion’s Chief Executive
Officer, commenting on the granting of this expanded patent stated,
“The approval of these claims to our existing patent strengthens
our patent for both domestic and international protection.”
About Guardion Health Sciences,
Inc.
Guardion® is an ocular health sciences company
that develops, formulates and distributes condition-specific
medical foods supported by evidence-based protocols, with an
initial medical food product that addresses a depleted macular
protective pigment, a known risk factor for age-related macular
degeneration (“AMD”), and a significant component of functional
vision performance. Guardion has also developed a proprietary
medical device, the MapcatSF®, which accurately measures the
macular pigment density, therefore providing the only two-pronged
evidence-based protocol for the treatment of a depleted macular
protective pigment.
About VectorVision®
VectorVision® specializes in the standardization
of contrast sensitivity, glare sensitivity, low contrast acuity,
and ETDRS acuity vision testing. Its patented standardization
system provides the practitioner or researcher the ability to
delineate very small changes in visual capability, either as
compared to the population or from visit to visit. VectorVision®’s
CSV-1000 device is considered the standard of care for clinical
trials. VectorVision® is a wholly-owned subsidiary of Guardion.
Guardion has completed development of the
proprietary VectorVision® CSV-2000 standardized contrast
sensitivity test and recently introduced the commercial product to
the marketplace. The CSV-2000 is the only computer-generated vision
testing instrument available that will provide the optical
marketplace with the Company’s proprietary, industry-standard
contrast sensitivity test, along with a full suite of standard
vision testing protocols. The proprietary standardization
methodology incorporated into the CSV-2000 includes a patented
technology known as AcQviz that automatically and constantly
measures and adjusts screen luminance to a fixed standard light
level for vision testing.
Forward-Looking Statement
Disclaimer
Certain statements in this press release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These statements
involve unknown risks and uncertainties that may individually or
materially impact the matters discussed herein for a variety of
reasons that are outside the control of the Company, including, but
not limited to, the Company’s ability to raise sufficient financing
to implement its business plan and its ability to successfully
develop and commercialize its proprietary products and
technologies. Readers are cautioned not to place undue reliance on
these forward-looking statements, as actual results could differ
materially from those described in the forward-looking statements
contained herein. Readers are urged to read the risk factors set
forth in the Company’s under the caption “Risk Factors” in the
Company’s’ Annual Report on Form 10-K for the year ended December
31, 2018 and the Company’s other filings made with SEC, which are
available at the SEC’s website (www.sec.gov). Forward-looking
statements included herein are made as of the date hereof, and the
Company does not undertake any obligation to update publicly such
statements to reflect subsequent events or circumstances.
Investor Relations Contact: Matthew
AbenantePorter, LeVay & Rose Telephone: (212) 564-4700 E-mail:
matthew@plrinvest.com
Guardion Health Sciences, Inc.15150 Avenue of
Science, Ste. 200 San Diego, CA 92128Ph 858.605.9055; Fax
858.630.5543www.guardionhealth.com
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Sep 2023 to Sep 2024